? BIOSPECIMEN SERVICES SHARED RESOURCE (BSSR) The mission of the BSSR is to support innovative translational research to advance the prevention, diagnosis, and treatment of cancer through the provision of biospecimens and clinical data.
The Specific Aims are to: 1) collect data and specimens from OSUCCC cancer patients using the IRB-approved Total Cancer Care (TCC) universal consenting and biobanking protocol for future unspecified research; 2) prospectively procure biospecimens for specific IRB-approved protocols; and 3) provide high quality, centralized biorepository services for IRB-approved, grant-funded and large institutional projects in a CAP-accredited biorepository. Over the current grant cycle, the major changes for the BSSR include: a) implementation of TCC across all Disease Specific Research Groups (DSRGs) covering all cancers - TCC now includes 57,256 consented subjects resulting in regular usage of biospecimens and data; and, b) the ORIEN AVATAR program was initiated, providing OSUCCC members with research grade next generation exome sequencing results on tumor and normal tissue with clinical annotation from 3,049 TCC subjects at OSU and 11,500 across ORIEN (the OSUCCC is a major contributor of samples). During the current grant cycle, the BSSR provided key services in support of 122 publications (35 > 10 impact factor), 105 users, and 24 NCI grants, including 1 K01, 1 K12, 2 P01s, 2 P50s, 11 R01s, 4 R21s, 1 U10, 1 UH2, and 1 UM1. Over the next grant cycle, BSSR will contribute to each of the new strategic priorities for the OSUCCC by providing biospecimens and high quality genomic and clinical data as requested by immuno-oncology, translational genomics, cancer engineering and cancer prevention and survivorship investigators. Each area will be supported by the TCC, and given the robust faculty recruitment and regularly increasing patient volumes; there will be an increase in prospective procurement and biobanking as well. Given the robust OSUCCC recruitment and increasing patient volumes, demand for services and new technologies will increase. The BBSR will expand its staff, instrumentation and services before capacity is reached. The annual budget of the BSSR is $2,206,277, yet the CCSG request is $179,168. As such, The BSSR leverages extensive institutional support and seeks only 8.1% support from CCSG funds.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016058-45
Application #
10090005
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
1997-09-12
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Shu, Yi; Yin, Hongran; Rajabi, Mehdi et al. (2018) RNA-based micelles: A novel platform for paclitaxel loading and delivery. J Control Release 276:17-29
Scoville, Steven D; Nalin, Ansel P; Chen, Luxi et al. (2018) Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function. Blood 132:1792-1804
McMillan, Elizabeth A; Ryu, Myung-Jeom; Diep, Caroline H et al. (2018) Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. Cell 173:864-878.e29
Schimizzi, Gregory V; Jin, Linda X; Davidson 4th, Jesse T et al. (2018) Outcomes after vascular resection during curative-intent resection for hilar cholangiocarcinoma: a multi-institution study from the US extrahepatic biliary malignancy consortium. HPB (Oxford) 20:332-339
Fu, Xinping; Tao, Lihua; Wang, Pin-Yi et al. (2018) Comparison of infectivity and spread between HSV-1 and HSV-2 based oncolytic viruses on tumor cells with different receptor expression profiles. Oncotarget 9:21348-21358
Brewington, Beatrice Y; Shao, Yusra F; Davidorf, Fredrick H et al. (2018) Brachytherapy for patients with uveal melanoma: historical perspectives and future treatment directions. Clin Ophthalmol 12:925-934
Doogan, Nathan J; Cooper, Sarah; Quisenberry, Amanda J et al. (2018) The role of travel distance and price promotions in tobacco product purchase quantity. Health Place 51:151-157
Byrd, John C; Ruppert, Amy S; Heerema, Nyla A et al. (2018) Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Adv 2:1705-1718
Oblinger, Janet L; Burns, Sarah S; Huang, Jie et al. (2018) Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation. Exp Neurol 299:299-307
Pan, Pan; Oshima, Kiyoko; Huang, Yi-Wen et al. (2018) Loss of FFAR2 promotes colon cancer by epigenetic dysregulation of inflammation suppressors. Int J Cancer 143:886-896

Showing the most recent 10 out of 2602 publications